

October 23, 2012

Ono Pharmaceutical Co., Ltd.
Corporate Communications
Tel: +81-6-6263-5670

Ono Enters into Collaboration Agreement with Domain Therapeutics in the Field of GPCR-Based Drug Discovery

Ono Pharmaceutical Co., Ltd. (Osaka Japan) announced today that Ono and Domain Therapeutics S.A. (Strasbourg, France) signed a collaboration agreement, focused on discovering novel small molecules targeting G-Protein Coupled Receptors (GPCRs).

Under the agreement, Ono will pay to Domain Therapeutics upfront payment, research funding for the collaborative research programs, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “We highly appreciate Domain Therapeutics’ DTect-All™ technology, and strongly believe that they are the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with Pharma partners on integrated projects, from target to drug candidate” commented Pascal Neuville, Domain Therapeutics’ Chief Executive Officer. “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting GPCRs, one of the most important classes of drug targets. Domain Therapeutics discovers GPCR drugs by exploiting its innovative and

differentiated approach. The company's pipeline is composed of new chemical entities, ranging from hits to optimized leads for significant CNS and metabolic disorders. Domain Therapeutics is also giving access to its proprietary technologies to pharmaceutical companies. For more information, please visit www.domaintherapeutics.com.

About GPCRs

GPCRs are members of a class of cell surface receptors conjugated with a G-protein, which signaling pathway is initiated by binding between the receptor and a hormone or bioactive molecule. GPCR targeted therapeutics comprise major drug classes in many disease areas, including CNS, metabolic, cardiovascular, respiratory, urinary and gastrointestinal.

About DTect-All™

Domain Therapeutics' proprietary technologies, named DTect-All™, is a screening technology that enables sensitive detection of compounds that bind to the targeted GPCR fused to a fluorescent protein like GFP by measuring change in fluorescence caused by interaction between the fluorescent protein and a fluorescent probe selected from Domain's proprietary probe collection. DTect-All™ allows generation of small molecule drugs for challenging GPCRs, which remain intractable when classical screening methods are employed.